XML 17 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure | 12 Months Ended
--- | ---
Dec. 31, 2024 USD ($) $ / shares | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($)
Pay vs Performance Disclosure |  |  |  |  |
Pay vs Performance Disclosure, Table | Pay Versus Performance The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the Compensation Committee view the link between the Company’s performance and named executive officer (“NEO”) pay. For additional information about our pay-for-performance philosophy and how we align executive compensation with Company performance, refer to the Compensation Discussion and Analysis beginning on page 27. Required Tabular Disclosure of Pay Versus Performance The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid for Non-PEO NEOs” have been calculated in a manner consistent with Item 402(v) of Regulation S-K. Use of the term “compensation actually paid” (“CAP”) is required by the SEC’s rules and as a result of the calculation methodology required by the SEC, such amounts differ from compensation actually received by the individuals and the compensation decisions described in the “Compensation Discussion and Analysis” section above.
(a) |  | (b) |  |  | (c) |  |  | (d) |  |  | (e) |  |  | (f) |  |  | (g) |  |  | (h) |  |  | (i) |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Value of Initial Fixed $100 Investment Based on:(4) |  |  |  |  |  |  |
Year |  | Summary Compensation Table Total for PEO ($)(1)(2) |  |  | Compensation Actually Paid to PEO ($)(3) |  |  | Average Summary Compensation Table Total for Non-PEO NEOs ($)(1)(2) |  |  | Average Compensation Actually Paid to Non-PEO NEOs ($)(1)(2) |  |  | Total Shareholder Return ($) |  |  | NASDAQ Biotechnology Index Total Shareholder Return ($) |  |  | Net Income (Loss) (thousands) ($)(5) |  |  | Total Revenue (thousands) ($)(6) |
2024 |  |  | 9,490,628 |  |  |  | 22,841,604 |  |  |  | 2,892,840 |  |  |  | 5,529,410 |  |  |  | 498.45 |  |  |  | 118.20 |  |  |  | 27,588 |  |  |  | 285,504 |
2023 |  |  | 7,068,114 |  |  |  | 96,764 |  |  |  | 2,201,163 |  |  |  | 351,865 |  |  |  | 282.17 |  |  |  | 118.87 |  |  |  | (11,938 | ) |  |  | 198,962 |
2022 |  |  | 3,905,058 |  |  |  | 9,653,678 |  |  |  | 1,481,321 |  |  |  | 2,201,087 |  |  |  | 408.53 |  |  |  | 113.65 |  |  |  | (87,400 | ) |  |  | 99,770 |
2021 |  |  | 4,030,833 |  |  |  | 7,317,812 |  |  |  | 1,730,384 |  |  |  | 3,037,694 |  |  |  | 338.76 |  |  |  | 126.45 |  |  |  | (80,926 | ) |  |  | 75,442 |
2020 |  |  | 3,563,295 |  |  |  | 7,424,884 |  |  |  | 1,613,615 |  |  |  | 3,137,880 |  |  |  | 242.64 |  |  |  | 126.42 |  |  |  | (57,240 | ) |  |  | 65,144 |
(1) | The following individuals are our PEO and other non-PEO NEOs for each fiscal year:
Year |  | PEO |  | Non-PEO NEOs
2024 |  | Michael E. Castagna |  | Christopher B. Prentiss, Steven B. Binder, Burkhard Blank, Lauren M. Sabella, and David B. Thomson
2023 |  | Michael E. Castagna |  | Steven B. Binder, Lauren M. Sabella, David B. Thomson, and Stuart A. Tross
2022 |  | Michael E. Castagna |  | Steven B. Binder, Alejandro Galindo, Joseph Kocinsky, Sanjay Singh, David B. Thomson, and Stuart A. Tross
2021 |  | Michael E. Castagna |  | Steven B. Binder, Joseph Kocinsky, David B. Thomson, and Stuart A. Tross
2020 |  | Michael E. Castagna |  | Steven B. Binder, Joseph Kocinsky, David B. Thomson, and Stuart A. Tross
(2) | The dollar amounts reported in column (b) and (d) are the amounts of total compensation reported for Mr. Castagna (our Chief Executive Officer and PEO) and the average total compensation for our non-PEO NEOs for each corresponding year in the “Total” column of the Summary Compensation Table. Refer to “Executive Compensation—Summary Compensation Table.”
(3) | The dollar amounts reported in column (c) and (e) represent the amount of CAP to Mr. Castagna and the average amount of CAP to our Non-PEO NEOs, respectively, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to our NEOs during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to the reported total compensation for each year to determine the CAP for the year ended December 31, 2024:
|  |  |  |  |  | PEO ($) |  |  | Average Non-PEO NEOs ($) |
Summary Compensation Table Total |  |  | 9,490,628 |  |  |  | 2,892,840 |
Deduct: Grant Date Fair Value of "Stock Awards” Column in the Summary Compensation Table for Applicable FY |  |  | (7,929,950 | ) |  |  | (2,108,794 | )
Add: Fair Value at Applicable FY End of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End (7) |  |  | 11,729,781 |  |  |  | 3,107,390 |
Add: Change in Fair Value of Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End (7) |  |  | 7,754,489 |  |  |  | 1,302,263 |
Add: Vesting Date Fair Value of Awards Granted during Applicable FY that Vested During Applicable FY |  | — |  |  |  | 23,621 |
Add: Vesting Date Fair Value of Awards Granted during Prior FY that Vested During Applicable FY |  |  | 1,796,656 |  |  |  | 312,090 |
Deduct: Fair Value at Prior Year End of Awards Granted during Prior FY that were Forfeited during Applicable FY |  | — |  |  | — |
Add: Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date |  | — |  |  | — |
CAP |  |  | 22,841,604 |  |  |  | 5,529,410 |
(4) | The amounts reflect the cumulative total shareholder return of our common stock (column (f)) and the NASDAQ Biotechnology Index (column (g)) at the end of each fiscal year. In each case, assume an initial investment of $100 on December 31, 2019, and reinvestment of dividends, if any.
(5) | The dollar amounts reported in column (h) represent the net income (loss) as reported in the Company’s audited financial statements for the applicable year.
(6) | As required by Item 402(v) of Regulation S-K, we have determined that Total Revenue is the Company-Selected Measure.
(7) | The fair values of PSUs and stock options vested during the fiscal year or outstanding as of fiscal year end were estimated using the Monte Carlo simulation model and Black-Scholes option valuation model, respectively. The following valuation assumptions used to calculate the fair values of these awards differed materially from the assumptions used to value the awards on their respective grant dates:
Assumptions |  | PSUs |  | Stock Options |
Term (years) |  | 0.36 — 2.49 |  | 1.00 — 2.00 |
Correlation Coefficient — MannKind |  | 0.25 — 0.43 |  | — |
Correlation Coefficient — Peer Average |  | 0.27 — 0.32 |  | — |
Correlation Coefficient — Peer Median |  | 0.27 — 0.33 |  | — |
Beginning Average Stock Price |  | $2.95—$5.09 |  | — |
Valuation Date Stock Price |  | $6.43 |  | $6.43 |
Initial TSR |  | 26.33% — 117.97% |  | — |
Risk-Free Rate |  | 4.16% — 4.26% |  | — |
Volatility — MannKind |  | 39.05% — 51.34% |  |  | 57.46 | %
Volatility — Peer Average |  | 66.98% — 73.92% |  | — |
Volatility — Peer Median |  | 59.77% — 72.12% |  | — |
Exercise Price |  | — |  | $1.42 — $4.55 |
Company Selected Measure Name | Total Revenue |  |  |  |
Named Executive Officers, Footnote |
Year |  | PEO |  | Non-PEO NEOs
2024 |  | Michael E. Castagna |  | Christopher B. Prentiss, Steven B. Binder, Burkhard Blank, Lauren M. Sabella, and David B. Thomson
2023 |  | Michael E. Castagna |  | Steven B. Binder, Lauren M. Sabella, David B. Thomson, and Stuart A. Tross
2022 |  | Michael E. Castagna |  | Steven B. Binder, Alejandro Galindo, Joseph Kocinsky, Sanjay Singh, David B. Thomson, and Stuart A. Tross
2021 |  | Michael E. Castagna |  | Steven B. Binder, Joseph Kocinsky, David B. Thomson, and Stuart A. Tross
2020 |  | Michael E. Castagna |  | Steven B. Binder, Joseph Kocinsky, David B. Thomson, and Stuart A. Tross
PEO Total Compensation Amount | $ 9,490,628 | $ 7,068,114 | $ 3,905,058 | $ 4,030,833 | $ 3,563,295
PEO Actually Paid Compensation Amount | 22,841,604 | 96,764 | 9,653,678 | 7,317,812 | 7,424,884
Non-PEO NEO Average Total Compensation Amount | 2,892,840 | 2,201,163 | 1,481,321 | 1,730,384 | 1,613,615
Non-PEO NEO Average Compensation Actually Paid Amount | $ 5,529,410 | 351,865 | 2,201,087 | 3,037,694 | 3,137,880
Adjustment to Non-PEO NEO Compensation Footnote |
|  |  |  |  |  | PEO ($) |  |  | Average Non-PEO NEOs ($) |
Summary Compensation Table Total |  |  | 9,490,628 |  |  |  | 2,892,840 |
Deduct: Grant Date Fair Value of "Stock Awards” Column in the Summary Compensation Table for Applicable FY |  |  | (7,929,950 | ) |  |  | (2,108,794 | )
Add: Fair Value at Applicable FY End of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End (7) |  |  | 11,729,781 |  |  |  | 3,107,390 |
Add: Change in Fair Value of Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End (7) |  |  | 7,754,489 |  |  |  | 1,302,263 |
Add: Vesting Date Fair Value of Awards Granted during Applicable FY that Vested During Applicable FY |  | — |  |  |  | 23,621 |
Add: Vesting Date Fair Value of Awards Granted during Prior FY that Vested During Applicable FY |  |  | 1,796,656 |  |  |  | 312,090 |
Deduct: Fair Value at Prior Year End of Awards Granted during Prior FY that were Forfeited during Applicable FY |  | — |  |  | — |
Add: Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date |  | — |  |  | — |
CAP |  |  | 22,841,604 |  |  |  | 5,529,410 |
Equity Valuation Assumption Difference, Footnote |
Assumptions |  | PSUs |  | Stock Options |
Term (years) |  | 0.36 — 2.49 |  | 1.00 — 2.00 |
Correlation Coefficient — MannKind |  | 0.25 — 0.43 |  | — |
Correlation Coefficient — Peer Average |  | 0.27 — 0.32 |  | — |
Correlation Coefficient — Peer Median |  | 0.27 — 0.33 |  | — |
Beginning Average Stock Price |  | $2.95—$5.09 |  | — |
Valuation Date Stock Price |  | $6.43 |  | $6.43 |
Initial TSR |  | 26.33% — 117.97% |  | — |
Risk-Free Rate |  | 4.16% — 4.26% |  | — |
Volatility — MannKind |  | 39.05% — 51.34% |  |  | 57.46 | %
Volatility — Peer Average |  | 66.98% — 73.92% |  | — |
Volatility — Peer Median |  | 59.77% — 72.12% |  | — |
Exercise Price |  | — |  | $1.42 — $4.55 |
Compensation Actually Paid vs. Total Shareholder Return |  |  |  |  |
Compensation Actually Paid vs. Net Income |  |  |  |  |
Compensation Actually Paid vs. Company Selected Measure |  |  |  |  |
Total Shareholder Return Vs Peer Group |  |  |  |  |
Tabular List, Table | The most important financial and non-financial performance measures used by the Company to link CAP to the Company’s NEOs for the most recently completed fiscal year to the company’s performance are set forth below. For further information regarding these performance metrics and their function in our executive compensation program, please see “Compensation Discussion and Analysis” beginning on page 27. • Total revenue; • Total shareholder return; • Deliver on Tyvaso DPI production; • Drive endocrinology business; and • Advance pipeline opportunities. |  |  |  |
Total Shareholder Return Amount | $ 498.45 | 282.17 | 408.53 | 338.76 | 242.64
Peer Group Total Shareholder Return Amount | 118.2 | 118.87 | 113.65 | 126.45 | 126.42
Net Income (Loss) | $ 27,588,000 | $ (11,938,000) | $ (87,400,000) | $ (80,926,000) | $ (57,240,000)
Company Selected Measure Amount | 285,504,000 | 198,962,000 | 99,770,000 | 75,442,000 | 65,144,000
PEO Name | Michael E. Castagna | Michael E. Castagna | Michael E. Castagna | Michael E. Castagna | Michael E. Castagna
Additional 402(v) Disclosure | All information provided above under the “Item 402(v) Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference. |  |  |  |
Measure:: 1 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Total revenue; |  |  |  |
Measure:: 2 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Total shareholder return; |  |  |  |
Measure:: 3 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Deliver on Tyvaso DPI production; |  |  |  |
Measure:: 4 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Drive endocrinology business; and |  |  |  |
Measure:: 5 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Advance pipeline opportunities. |  |  |  |
PSUs [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Term (years), Minimum | 4 months 9 days |  |  |  |
Term (years), Maximum | 2 years 5 months 26 days |  |  |  |
Correlation Coefficient - MannKind, Minimum | 0.25 |  |  |  |
Correlation Coefficient - MannKind, Maximum | 0.43 |  |  |  |
Correlation Coefficient - Peer Average, Minimum | 0.27 |  |  |  |
Correlation Coefficient - Peer Average, Maximum | 0.32 |  |  |  |
Correlation Coefficient - Peer Median Miminum | 0.27 |  |  |  |
Correlation Coefficient - Peer Median Maximum | 0.33 |  |  |  |
Beginning Average Stock Price, Minimum | $ / shares | $ 2.95 |  |  |  |
Beginning Average Stock Price, Maximum | $ / shares | 5.09 |  |  |  |
Valuation Date Stock Price | $ / shares | $ 6.43 |  |  |  |
Initial TSR, Minimum | (26.33%) |  |  |  |
Initial TSR, Maximum | 117.97% |  |  |  |
Risk-Free Rate, Minimum | 4.16% |  |  |  |
Risk-Free Rate, Maximum | 4.26% |  |  |  |
Volatility - MannKind, Minimum | 39.05% |  |  |  |
Volatility - MannKind, Maximum | 51.34% |  |  |  |
Volatility - Peer Average, Minimum | 66.98% |  |  |  |
Volatility - Peer Average, Maximum | 73.92% |  |  |  |
Volatility - Peer Median, Minimum | 59.77% |  |  |  |
Volatility - Peer Median, Maximum | 72.12% |  |  |  |
Stock Options [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Term (years), Minimum | 1 year |  |  |  |
Term (years), Maximum | 2 years |  |  |  |
Valuation Date Stock Price | $ / shares | $ 6.43 |  |  |  |
Volatility - MannKind | 57.46 |  |  |  |
Exercise Price, Minimum | $ / shares | $ 1.42 |  |  |  |
Exercise Price, Maximum | $ / shares | $ 4.55 |  |  |  |
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ (7,929,950) |  |  |  |
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 11,729,781 |  |  |  |
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 7,754,489 |  |  |  |
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 1,796,656 |  |  |  |
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (2,108,794) |  |  |  |
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 3,107,390 |  |  |  |
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  | $ 1,302,263 |  |  |
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 23,621 |  |  |  |
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ 312,090 |  |  |  |

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v + Details
Name: | ecd_Additional402vDisclosureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 4 + Details
Name: | ecd_EquityValuationAssumptionDifferenceFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption beginning average stock price maximum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionBeginningAverageStockPriceMaximum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption beginning average stock price minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionBeginningAverageStockPriceMinimum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption difference correlation coefficient mannkind maximum + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionDifferenceCorrelationCoefficientMannkindMaximum
Namespace Prefix: | mnkd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption difference correlation coefficient mannkind minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionDifferenceCorrelationCoefficientMannkindMinimum
Namespace Prefix: | mnkd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption difference correlation coefficient peer average maximum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionDifferenceCorrelationCoefficientPeerAverageMaximum
Namespace Prefix: | mnkd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption difference correlation coefficient peer average minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionDifferenceCorrelationCoefficientPeerAverageMinimum
Namespace Prefix: | mnkd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption difference correlation coefficient peer median maximum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionDifferenceCorrelationCoefficientPeerMedianMaximum
Namespace Prefix: | mnkd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Valuation Assumption Difference Correlation Coefficient Peer Median Minimum + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionDifferenceCorrelationCoefficientPeerMedianMinimum
Namespace Prefix: | mnkd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption exercise price maximum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionExercisePriceMaximum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption exercise price minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionExercisePriceMinimum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption initial TSR maximum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionInitialTsrMaximum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption initial TSR minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionInitialTsrMinimum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption risk-free rate maximum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionRiskFreeRateMaximum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption risk-free rate minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionRiskFreeRateMinimum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption term maximum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionTermMaximum
Namespace Prefix: | mnkd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption term minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionTermMinimum
Namespace Prefix: | mnkd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption valuation date stock price. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionValuationDateStockPrice
Namespace Prefix: | mnkd_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption volatility — mannkind minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionVolatilityMannkind
Namespace Prefix: | mnkd_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption volatility mannkind maximum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionVolatilityMannkindMaximum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption volatility — mannkind minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionVolatilityMannkindMinimum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption volatility peer average maximum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionVolatilityPeerAverageMaximum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption volatility peer average minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionVolatilityPeerAverageMinimum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption volatility peer median maximum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionVolatilityPeerMedianMaximum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity valuation assumption volatility peer median minimum. + References No definition available. + Details
Name: | mnkd_EquityValuationAssumptionVolatilityPeerMedianMinimum
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=4
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=5
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=mnkd_PsusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=mnkd_StockOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |